+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chagas Disease (American Trypanosomiasis) R&D Pipeline Analysis Report, H2-2018

  • ID: 4614252
  • Report
  • Region: United States
  • 70 pages
  • VPA Research
UP TO OFF
until Sep 30th 2019
1 of 3
Comprehensive Pipeline Review on Ongoing Clinical and Pre-Clinical Studies

FEATURED COMPANIES

  • Bayer AG
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Johnson & Johnson
  • Kancera AB
  • Novartis AG
  • MORE
Chagas Disease (American Trypanosomiasis) Drug Development Pipeline Study is the latest publication from this researcher with comprehensive information of Chagas Disease (American Trypanosomiasis) pipeline products.

The Chagas Disease (American Trypanosomiasis) pipeline guide presents complete overview of drugs currently being developed for Chagas Disease (American Trypanosomiasis). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Chagas Disease (American Trypanosomiasis) pipeline candidate.
Research and Development progress along with latest news related to each of the Chagas Disease (American Trypanosomiasis) pipeline candidates is included.

Major companies participating in therapeutic development of Chagas Disease (American Trypanosomiasis) are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Chagas Disease (American Trypanosomiasis) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chagas Disease (American Trypanosomiasis) clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in Chagas Disease (American Trypanosomiasis) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Chagas Disease (American Trypanosomiasis) pipeline report includes
  • Panorama of Chagas Disease (American Trypanosomiasis) pipeline markets including statistics on therapeutic drugs and companies involved
  • Chagas Disease (American Trypanosomiasis) Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
  • Chagas Disease (American Trypanosomiasis) pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Chagas Disease (American Trypanosomiasis) pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Chagas Disease (American Trypanosomiasis) pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Chagas Disease (American Trypanosomiasis) pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Chagas Disease (American Trypanosomiasis) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Please Note: The report will be delivered in 2 working days after purchase
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bayer AG
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Johnson & Johnson
  • Kancera AB
  • Novartis AG
  • MORE
I. Key Findings

1. Companies Investing in Chagas Disease (American Trypanosomiasis) Pipeline include
Number of Companies with Chagas Disease (American Trypanosomiasis) projects in pre clinical Development
Number of Companies with Chagas Disease (American Trypanosomiasis) projects in Clinical Development
Chagas Disease (American Trypanosomiasis) Pipeline Companies based in Americas
Chagas Disease (American Trypanosomiasis) Pipeline Companies based in Europe
Chagas Disease (American Trypanosomiasis) Pipeline Companies based in Asia Pacific
Chagas Disease (American Trypanosomiasis) Pipeline Companies based in Rest of the World

2. Pipeline Candidates include
Chagas Disease (American Trypanosomiasis) Pipeline Agents in pre clinical/ Discovery stage of Development
Chagas Disease (American Trypanosomiasis) Pipeline Agents in Clinical Development stage
Chagas Disease (American Trypanosomiasis) Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Chagas Disease (American Trypanosomiasis) Pipeline agents

II. Insights into Chagas Disease (American Trypanosomiasis) Pipeline -

1. Disease Overview
Introduction to Chagas Disease (American Trypanosomiasis)
Symptoms and Causes of Chagas Disease (American Trypanosomiasis)
Treatment or Prevention Options for Chagas Disease (American Trypanosomiasis)
Other Details
2. Phase wise Pipeline Compounds
Chagas Disease (American Trypanosomiasis) Pipeline Pre Clinical/ Discovery stage Drugs
Chagas Disease (American Trypanosomiasis) Pipeline Phase 1 stage Drugs
Chagas Disease (American Trypanosomiasis) Pipeline Phase 2 stage Drugs
Chagas Disease (American Trypanosomiasis) Pipeline Phase 3 stage Drugs
Chagas Disease (American Trypanosomiasis) Pipeline Pre Registration stage Drugs
3. Company wise Chagas Disease (American Trypanosomiasis) Pipeline Compounds
4. Chagas Disease (American Trypanosomiasis) Pipeline by Mechanism of Action

III. Chagas Disease (American Trypanosomiasis) Pipeline Compound Details

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Chagas Disease (American Trypanosomiasis) Pipeline Company Briefs

V. Latest News and Developments in Global Chagas Disease (American Trypanosomiasis) Pipeline Market

VI. Appendix
1. About Us
2. Research Methodology
3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bayer AG
  • Collaborations Pharmaceuticals
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Johnson & Johnson
  • Kancera AB
  • Novartis AG
  • Oblita Therapeutics BVBA
  • RIKEN
  • Sanofi
  • Vyera Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll